Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

There are two styles to choose from: the default, Animation, which is like a 3D image; and Illustration, which is more flat and cartoony. Apple might add more styles in the future. There's also an ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

We reviewed the best free Adobe Illustrator alternatives for managing graphics files without a Creative Cloud subscription. We've rounded-up our top-rated choices for when you want to make the ...

1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...

The Science Illustration Internship is a full-time program (40 hours/week) for nine weeks (with a possible 10th week, if needed for any certifications), from June 2nd - August 1st, 2025 (Please note ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...